Investor Presentation Q1 2023

98 Investor presentation First three months of 2023 Novo NordiskⓇ There is broad potential for cell therapies and Novo Nordisk has capabilities to explore the potential Broad potential for clinical use of cell therapies Parkinson's disease Stroke Alzheimer's disease Dry AMD Blindness Hearing loss Congenital bone disorders Chronic heart failure Spinal cord injury Chronic kidney disease NASH Diabetes Osteoarthritis Muscular dystrophy Multiple sites: Cancers and wound healing Maturing the platform to enable development of competitive cell therapies Novo Nordisk capabilities In-depth know-how on Focus area Pluripotent stem cell embryonic pluripotent stem cells Bank of several undifferentiated stem Exploitation of quality controlled stem cells cells Differentiated to specific cell types Upscaling, manufacturing and delivery/devices Clinical development and regulatory affairs IP-protected protocols for differentiation GMP-grade cell manufacturing. and development of cell delivery devices¹ Early interactions with regulators Clinical trial experience 1In collaboration with academia and industrial partners Dry AMD: Dry age-related macular degeneration; NASH: Non-alcoholic steatohepatitis; IP: Intellectual property; GMP: Good manufacturing practices

View entire presentation